The company said it is evaluating its strategic options regarding ADX-097 as it shifts efforts over to pushing bempikibart.

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

inhibitor for adolescents with severe alopecia areata (AA), offers distinct properties that make it suitable for younger patients, and how its introduction influences treatment decisions and ...

section. Alopecia areata may cause other symptoms besides hair loss. Examples include discolored hair and a burning or itching sensation near the affected area. Doctors prescribe Olumiant to treat ...

Alopecia refers to hair loss and can affect the scalp, eyebrows, eyelashes, and other areas of the body. There are different types of alopecia including an | Immunology ...

Neehar Sachdeva is a popular Instagram influencer who recently got married and is trending as she is suffering from Alopecia.

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced a corporate restructuring to ...

Atopy from food allergies to environmental factors can increase hair loss prevalence among children and adults, according to ...

Q32 Bio (Nasdaq: QTTB) has announced a corporate restructuring, shifting its focus entirely to the development of its lead ...

WALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a clinical-stage biotechnology firm trading at $3.18 with a market cap of $38.55 million, announced a strategic shift to prioritize the development of its ...